S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
New Trump Bombshell (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
New Trump Bombshell (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
New Trump Bombshell (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
New Trump Bombshell (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
New Trump Bombshell (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
New Trump Bombshell (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
New Trump Bombshell (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
New Trump Bombshell (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
New Trump Bombshell (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
How this AP photographer captured a unique splash at the swimming worlds with an underwater camera
New Trump Bombshell (Ad)
Delays in promised Western military aid to Ukraine are costing lives, the defense minister says
MILAN FASHION PHOTOS: Feben, Rave Review promote looks for women of all shapes, ages and sizes
New Trump Bombshell (Ad)
Caribbean leaders meet with Haiti's prime minister. Foreign force deployment is on the agenda
What recession? Professional forecasters raise expectations for US economy in 2024
New Trump Bombshell (Ad)
Stock market today: Asian shares mostly decline, while Tokyo again touches a record high
AT&T will give $5 to customers hit by cellphone network outage

Palisade Bio (PALI) Competitors

$0.40
-0.02 (-4.38%)
(As of 02/23/2024 08:53 PM ET)

PALI vs. FNCH, KRBP, ALBT, NSTG, FRTX, NSTGQ, ELOX, TCON, TTNP, and CELZ

Should you be buying Palisade Bio stock or one of its competitors? The main competitors of Palisade Bio include Finch Therapeutics Group (FNCH), Kiromic BioPharma (KRBP), Avalon GloboCare (ALBT), NanoString Technologies (NSTG), Fresh Tracks Therapeutics (FRTX), NanoString Technologies (NSTGQ), Eloxx Pharmaceuticals (ELOX), TRACON Pharmaceuticals (TCON), Titan Pharmaceuticals (TTNP), and Creative Medical Technology (CELZ). These companies are all part of the "biological products, except diagnostic" industry.

Palisade Bio vs.

Palisade Bio (NASDAQ:PALI) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, community ranking, profitability, valuation and analyst recommendations.

Palisade Bio presently has a consensus price target of $8.75, indicating a potential upside of 2,065.84%. Finch Therapeutics Group has a consensus price target of $210.00, indicating a potential upside of 8,577.69%. Given Finch Therapeutics Group's higher possible upside, analysts clearly believe Finch Therapeutics Group is more favorable than Palisade Bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Palisade Bio
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Finch Therapeutics Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Palisade Bio has higher earnings, but lower revenue than Finch Therapeutics Group.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Palisade BioN/AN/A-$14.26MN/AN/A
Finch Therapeutics Group$860K4.53-$114.65M-$62.60-0.04

Finch Therapeutics Group received 4 more outperform votes than Palisade Bio when rated by MarketBeat users. Likewise, 52.63% of users gave Finch Therapeutics Group an outperform vote while only 37.50% of users gave Palisade Bio an outperform vote.

CompanyUnderperformOutperform
Palisade BioOutperform Votes
6
37.50%
Underperform Votes
10
62.50%
Finch Therapeutics GroupOutperform Votes
10
52.63%
Underperform Votes
9
47.37%

In the previous week, Finch Therapeutics Group had 1 more articles in the media than Palisade Bio. MarketBeat recorded 1 mentions for Finch Therapeutics Group and 0 mentions for Palisade Bio. Finch Therapeutics Group's average media sentiment score of 0.92 beat Palisade Bio's score of 0.00 indicating that Finch Therapeutics Group is being referred to more favorably in the news media.

Company Overall Sentiment
Palisade Bio Neutral
Finch Therapeutics Group Positive

1.9% of Palisade Bio shares are owned by institutional investors. Comparatively, 15.4% of Finch Therapeutics Group shares are owned by institutional investors. 2.2% of Palisade Bio shares are owned by company insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Palisade Bio's return on equity of -93.04% beat Finch Therapeutics Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Palisade BioN/A -93.04% -78.63%
Finch Therapeutics Group N/A -134.64%-66.66%

Palisade Bio has a beta of 1.42, meaning that its stock price is 42% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 0.41, meaning that its stock price is 59% less volatile than the S&P 500.

Summary

Finch Therapeutics Group beats Palisade Bio on 9 of the 13 factors compared between the two stocks.


Get Palisade Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for PALI and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PALI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PALI vs. The Competition

MetricPalisade BioBiological Products IndustryMedical SectorNASDAQ Exchange
Market Cap$3.75M$2.73B$4.82B$7.46B
Dividend YieldN/A2.35%5.40%3.86%
P/E RatioN/A10.02244.0318.27
Price / SalesN/A199.823,023.6968.34
Price / CashN/A21.2590.7154.77
Price / Book0.104.054.384.77
Net Income-$14.26M$73.80M$108.96M$205.13M
7 Day Performance-6.09%1.54%112.79%0.64%
1 Month Performance-22.31%11.45%121.55%7.69%
1 Year Performance-81.30%22.23%133.39%6.22%

Palisade Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FNCH
Finch Therapeutics Group
1.0407 of 5 stars
$2.42
-3.2%
$210.00
+8,577.7%
-77.9%$3.90M$860,000.00-0.0418Gap Down
KRBP
Kiromic BioPharma
0 of 5 stars
$3.02
+2.7%
N/A-32.2%$3.90MN/A0.0031Gap Up
ALBT
Avalon GloboCare
0 of 5 stars
$0.39
+2.6%
N/A-84.5%$4.29M$1.23M0.005
NSTG
NanoString Technologies
3.4445 of 5 stars
N/A$7.63
+∞
N/A$5.07M$127.26M-0.03550Upcoming Earnings
Gap Down
FRTX
Fresh Tracks Therapeutics
0 of 5 stars
$0.91
-8.1%
N/A-48.9%$5.44M$10.06M-0.3413Positive News
Gap Down
High Trading Volume
NSTGQ
NanoString Technologies
0 of 5 stars
$0.05
-16.7%
N/AN/A$2.41M$127.26M-0.01550Gap Up
ELOX
Eloxx Pharmaceuticals
2.1374 of 5 stars
$0.76
flat
$55.00
+7,127.3%
-74.4%$2.39MN/A-0.0818
TCON
TRACON Pharmaceuticals
0.9766 of 5 stars
$0.19
flat
$4.33
+2,228.5%
-89.8%$5.80M$350,000.00-0.3218Gap Down
TTNP
Titan Pharmaceuticals
0 of 5 stars
$7.82
+9.8%
N/A-57.3%$5.87M$560,000.000.004Gap Down
CELZ
Creative Medical Technology
0 of 5 stars
$4.31
+1.9%
N/A-36.5%$5.95M$90,000.00-0.554

Related Companies and Tools

This page (NASDAQ:PALI) was last updated on 2/26/2024 by MarketBeat.com Staff